Compare Stocks

Apogee Enterprises, Inc. provides architectural products and services for enclosing buildings, and glass and acrylic products used for preservation, protection, and enhanced viewing in the United States, Canada, and Brazil. The company operates in four segments: Architectural Framing Systems, Architectural Glass, Architectural Services, and Large-Scale Optical (LSO). The Architectural Framing Systems segment designs, engineers, fabricates, finishes, and installs custom glass and aluminum window, curtainwall, storefront, and entrance systems for the exterior of buildings primarily in the non-residential construction sectors. The Architectural Glass segment provides a range of high-performance glass products for use in windows, curtainwall, storefront, and entrance systems. The Architectural Services segment integrates technical services, project management, and field installation services to design, engineer, fabricate, and install building glass and curtainwall systems. The LSO segment manufactures high-performance glazing products for the custom framing, fine art, and engineered optics markets. The company's products and services are primarily used in commercial buildings, such as office buildings, hotels, and retail centers; institutional buildings comprising education facilities, health care facilities, and government buildings; transportation facilities, such as airports and transit terminals, as well as multi-family residential buildings. It markets its architectural products and services through direct sales force, independent sales representatives, distributors, and glazing subcontractors and general contractors; and value-added glass and acrylics through retail chains, as well as independent distributors to museums, galleries, and other customers. The company was incorporated in 1949 and is based in Minneapolis, Minnesota.

Chase Corporation, a specialty chemicals company, engages in the manufacture and sale of protective materials for various applications in North America, Asia, the Middle East, Europe, and internationally. It operates through three segments: Adhesives, Sealants and Additives; Industrial Tapes; and Corrosion Protection and Waterproofing. The Adhesives, Sealants and Additives segment offers protective conformal and moisture protective electronic coatings and cleaning solutions; advanced adhesives, sealants, and coatings; polymeric microspheres; polyurethane dispersions; superabsorbent polymers; and cleaning and protection solutions for electronic assemblies. The Industrial Tapes segment provides wire and cable materials; specialty tapes and related products; insulating and conducting materials; laminated durable papers; water-blocking compounds; laminated film foils and cover tapes; and pulling and detection tapes. The Corrosion Protection and Waterproofing segment offers protective pipe-coating tapes and other protectants; polymeric asphalt additives; waterproofing membranes; waterproofing sealants, expansion joints, and accessories; technological products, and tapes and membranes; specialized high-performance coating and lining systems; waterproofing and corrosion protection systems; and pipeline protection tapes and products. It serves transportation, appliances, medical, general industrial, cable manufacturing, utilities and telecommunications, and electronics packaging markets, as well as oil companies, gas companies, and water/wastewater utilities. The company sells the products through its salespeople, as well as manufacturers' representatives and distributors. Chase Corporation was founded in 1946 and is headquartered in Westwood, Massachusetts.

China High Speed Transmission Equipment Group Co., Ltd., together with its subsidiaries, engages in the manufacture of high-speed and heavy-duty gears for wind-turbine gearboxes and transmission systems in the People's Republic of China, the United States, Europe, and internationally. It focuses on wind energy gearboxes, rail vehicle gearboxes, industrial gearboxes, and robot reducers. In addition, the company engages in trading businesses. China High Speed Transmission Equipment Group Co., Ltd. was founded in 1969 and is headquartered in Causeway Bay, Hong Kong. China High Speed Transmission Equipment Group Co., Ltd. operates as a subsidiary of Five Seasons XVI Limited.

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.